The global prevalence of primary immunodeficiency
is rising, giving impetus to the global intravenous
immunoglobulins market. A report is published by Fortune Business Insights, titled “Intravenous Immunoglobulins:
Global Market Analysis, Insights and Forecast, 2018-2025,” offers in-depth insights
into the market. As per the report, in 2017 the global market was worth US$ 9,787.6 Mn. The market is anticipated to further expand at a CAGR of 6.2% and
reach US$ 15,789.1 by the end of 2025.
 |
| Get Sample PDF Brochure |
In terms of indication, the report
classifies the global market in primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy
(CIDP), and others. Primary immunodeficiency was leading the market in
2017. The segment accounted for 28.6% of the global market in 2017. During the
forecast period 2018-2025, the segment is likely to witness expansion at an
impressive pace. Diagnosis of primary immunodeficiency is gaining momentum and
encouraging the adoption of intravenous
immunoglobulins. Moreover, e patients who are incapable to perform
self-intervention of immunoglobulin are
further generating high demand in the intravenous immunoglobulins market. Besides
this, the chronic inflammatory demyelinating
polyneuropathy segment is forecast to show a slower growth owing to the low
prevalence of the disease the segment may witness slow growth.
"Intravenous Immunoglobulin Application in
Hospitals to Rise Persistently"
Intravenous immunoglobulin is the most
common route of administration of immunoglobulins, which is the chief driver of
the global market. The rising demand from hospitals and specialty clinics is anticipated
to encourage the adoption of intravenous immunoglobulins. Furthermore, key companies
are increasingly investing in research and development of advanced intravenous
immunoglobulins. Such researches are likely to enable growth in the market over
the forecast period.
Immunoglobulins are proven to be one
of the best treatment options for various immune diseases. Owing to the high
popularity of immunoglobulins, the market is foreseen to witness high demand.
On the contrary, factors that may
restrain the global intravenous immunoglobulins market are side effects
associated with Intravenous immunoglobulins and intravenous immunoglobulin’s
high cost.
"North America to Continue Dominating Global
Market"
The North America intravenous
immunoglobulins market was worth US$ 5,587.4 Mn in 2017. The region is further expected to emerge dominant over the forecast
period. The increasing number of patients in the region is anticipated to drive
the regional market. Moreover, in terms of dominance of route of administration, intravenous (IV) is the most
dominating type in developing nations. This is likely to enable growth in
market. Besides this, the advanced intravenous immunoglobulins are rapidly
adopted in developed nations. This in response if fueling the demand in market.
Asia Pacific is anticipated to expand at a promising CAGR. Owing to the high
prevalence of primary immunodeficiency in Asian population, the market is
foreseen to witness demand for immunoglobulin.
Read More in this Press Release:
The competition
among the key players is increasing. Owing to the prevailing opportunities,
players are focusing on the adoption of innovative strategies to gain a strong
brand presence. In 2017 Grifols, S.A. was leading the global market owing to
its diverse product portfolio. The Grifols, S.A. also holds a major share in
the European and North America intravenous immunoglobulins market. Other key
companies operating in the global intravenous immunoglobulins market are CSL
Behring, Grifols, S.A., Kedrion S.p.A, Octapharma, Bio Products Laboratory
Ltd., Biotest AG, China Biologic Products Holdings, Inc., LFB SA, and Shanghai
RAAS Blood Products Co., Ltd.
Get More Details Here:
No comments:
Post a Comment